This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Mithra Pharmaceuticals Future Growth
Future criteria checks 1/6
Mithra Pharmaceuticals is forecast to grow earnings and revenue by 79% and 14.1% per annum respectively while EPS is expected to grow by 94.4% per annum.
Key information
79.0%
Earnings growth rate
94.37%
EPS growth rate
Pharmaceuticals earnings growth
10.2%
Revenue growth rate
14.1%
Future return on equity
n/a
Analyst coverage
Low
Last updated
26 Oct 2023
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
BATS-CHIXE:MITRAb - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2025
95
8
73
82
3
12/31/2024
59
-29
-21
-12
3
12/31/2023
71
-39
-7
2
3
6/30/2023
63
-79
-28
-9
N/A
3/31/2023
65
-69
-55
-33
N/A
12/31/2022
67
-60
-82
-57
N/A
9/30/2022
44
-76
-92
-68
N/A
6/30/2022
22
-93
-102
-78
N/A
3/31/2022
22
-105
-100
-78
N/A
12/31/2021
23
-117
-98
-77
N/A
9/30/2021
21
-115
-94
-75
N/A
6/30/2021
19
-113
-91
-73
N/A
3/31/2021
14
-103
-94
-77
N/A
12/31/2020
9
-92
-96
-80
N/A
9/30/2020
44
-31
-85
-70
N/A
6/30/2020
79
29
-73
-59
N/A
3/31/2020
88
1
-68
-53
N/A
12/31/2019
97
-27
-62
-47
N/A
9/30/2019
84
-54
-42
-28
N/A
6/30/2019
71
-82
-21
-5
N/A
3/31/2019
64
-55
-14
-1
N/A
12/31/2018
58
-28
-7
4
N/A
9/30/2018
46
-41
-23
-9
N/A
6/30/2018
33
-53
-40
-25
N/A
3/31/2018
33
-46
-44
-28
N/A
12/31/2017
32
-38
-47
-31
N/A
9/30/2017
26
-37
-47
-32
N/A
6/30/2017
20
-36
-46
-32
N/A
3/31/2017
21
-36
N/A
-28
N/A
12/31/2016
22
-35
N/A
-23
N/A
9/30/2016
21
-29
N/A
-23
N/A
6/30/2016
20
-23
N/A
-22
N/A
3/31/2016
20
-16
N/A
-20
N/A
12/31/2015
20
-10
N/A
-18
N/A
9/30/2015
19
-9
N/A
-15
N/A
6/30/2015
18
-8
N/A
-12
N/A
3/31/2015
19
-5
N/A
-6
N/A
12/31/2014
19
-3
N/A
-1
N/A
12/31/2013
18
-2
N/A
1
N/A
12/31/2012
15
-1
N/A
1
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MITRAb is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MITRAb is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MITRAb is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MITRAb's revenue (14.1% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: MITRAb's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MITRAb's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/11/05 12:29
End of Day Share Price
2023/08/08 00:00
Earnings
2023/06/30
Annual Earnings
2022/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mithra Pharmaceuticals SA is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.